<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456842</url>
  </required_header>
  <id_info>
    <org_study_id>001/2018</org_study_id>
    <nct_id>NCT04456842</nct_id>
  </id_info>
  <brief_title>Cardiovascular Registry of Atrial Fibrillation</brief_title>
  <acronym>LACROSS</acronym>
  <official_title>Cardiovascular Registry of Atrial Fibrillation in Latin America: The LACROSS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilian Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brazilian Clinical Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Follow a representative sample of Latin American patients diagnosed with atrial fibrillation
      to set data on demographic characteristics, documenting antithrombotic therapy, describe the
      INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke,
      hemorrhage and death
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be followed 6 months and 1 year after the baseline visit and will be collected
      data of antithrombotic therapy, laboratory data, discontinuation rates of antithrombotic
      therapy and clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>INR control rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral anticoagulation discontinuation rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of death</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of stroke</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of systemic embolism</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of major bleeding</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of electrical cardioversion</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of percutaneous ablation of AF</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of atrioventricular junction ablation</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients that need of pacemaker implantation</measure>
    <time_frame>12 monts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of other cardiovascular hospitalization</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Registry Data</intervention_name>
    <description>To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with Atrial Fibrilation or Atrial Flutter
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years-old that signed informed consent;

          -  Atrial Fibrillation or Atrial Flutter at the time of inclusion documented in source
             document;

          -  If the patient is not in atrial fibrillation or Atrial Flutter rhythm, s/he should
             have 2 electrographic records, at least 15 days apart between them, with one of them
             being performed within the last 6 months before enrollment (AF may be documented by
             12-lead ECG, Holter monitor-24h);

        Exclusion Criteria:

          -  Patients who did not agree to participate.

          -  Patients without possibility of monitoring for one year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato D. Lopes, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Brasileiro de Pesquisa Thomaz de Carvalho - BCRI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renato D. Lopes, MD, PhD</last_name>
    <phone>55 11 5904 7339</phone>
    <email>renato.lopes@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Alvorada Taguatinga Ltda</name>
      <address>
        <city>SÃ£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Pedro Gabriel Melo de Barros e Silva, MD, PhD</last_name>
      <email>drpedrobarros80@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrilation</keyword>
  <keyword>Antithrombotic therapy</keyword>
  <keyword>Atrial Flutter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

